This research study aims to better understand how the brain and body change during physical or occupational therapy after a neurologic injury or condition. Adults who are already receiving outpatient neurorehabilitation will be invited to participate while they complete their regular therapy sessions. During therapy, participants will wear a lightweight cap that measures brain activity and will be video recorded so researchers can analyze movement patterns using computer software. These recordings do not change therapy activities and are for research purposes only. The study does not involve new treatments, medications, or procedures beyond standard care. Information collected may help researchers understand why recovery differs between individuals and improve future rehabilitation approaches.

This study is testing a new therapy called GRIEF Approach (Grief Recovery with Individualized Evidence-Based Formulation) to help adults who have lost a loved one to a sudden or violent death, such as suicide, homicide, drug overdose, or car crash. Many people who experience this type of loss develop depression, post-traumatic stress, and/or prolonged grief, and current treatments often fail to address all of these symptoms together. GRIEF Approach is a flexible, individualized therapy that combines evidence-based strategies to address traumatic stress, grief, and depression within a single treatment. The primary goal of this study is not to test whether the therapy works, but to evaluate whether it is feasible and acceptable to patients and therapists. Participants will complete mood and symptom questionnaires at the start of the study, weekly during treatment, and one month after treatment ends. Participants will also provide feedback on their experience with the therapy through questionnaires and brief interviews. Findings from this study will be used to refine the treatment and study procedures in preparation for a larger clinical trial.

We are recruiting healthy volunteers, age 18-65, for a 4-visit study designed to test whether brief non-invasive brain stimulation, called transcranial focused ultrasound (tFUS), changes how adults process pictures and odors. In addition to 3 tFUS sessions, the study procedures also include one 30-minute magnetic resonance imaging (MRI) session and four 1-hour encephalography (EEG) sessions during which we will measure brain structure and function. Each of the 4 visits last about 2-3 hours and should occur over a 2-4-week time period. Compensation is available to those that qualify.

This study will examine sex differences in the effects of cannabis in people that regularly use it. Men and women that use cannabis at least 4 days a week will participate in a study involving 1-3 in-person visits. The first visit will be used to determine eligibility for the study and will include a blood draw for genetic testing. Most participants will only complete the first visit. Participants that are eligible for the second part of the study will complete two additional visits. These two visits will last 7 hours each and take place at least two days apart. Visits include administration of either THC, the chemical responsible for many of the psychoactive effects of cannabis, or a placebo; completion of questionnaires; repeated blood draws; and a 1-hour brain scan.

This study is testing whether an investigational compound called oleoylethanolamide (OEA) may help reduce alcohol use in young adults with alcohol use disorder. Young adults ages 18-25 will be randomly assigned to receive either OEA (250mg per day) or a placebo for six weeks. Researchers will measure alcohol use, immune function, oral bacteria, and thinking and decision-making. Compensation is available for those who qualify.

The purpose of this study is to measure the efficacy and safety of KP-001 compared to placebo in patients with common venous malformations (VM), common lymphatic malformations (LM), or KTS/CLOVES syndrome. This phase 3, double-blind, randomized, placebo-controlled, parallel-group study will take place at multiple sites across North America. Vascular malformations like VM, LM, and KTS/CLOVES syndrome are serious, rare diseases with significant unmet medical needs. The study includes a 24-week double-blind treatment period with either KP-001 or placebo, followed by an open-label phase where all patients receive KP-001 up to Week 52. Patients weighing 40 kg or more will receive 100 mg of KP-001 once daily after breakfast, while those weighing less than 40 kg will receive a reduced dose based on their body weight.

This study will enroll patients that were either diagnosed with hepatocellular cancer (HCC) in the past 6 weeks or have been diagnosed with cirrhosis but do not have HCC. Patients will have a blood sample collected to test if a new blood-based biomarker is accurate in the early detectection of HCC.

This research study is being conducted at the Medical University of South Carolina (MUSC). The purpose of this study is to better understand injury to the small nerves that run between the ribs following rib fractures, and to learn what normal sensation and muscle appearance of the abdominal wall (muscles of the stomach area) look like in healthy adults. This information will help doctors better recognize and diagnose nerve injuries in patients who have had trauma, surgery, or other conditions affecting the abdominal wall.

Researchers will use simple sensory testing of the skin of the abdomen and ultrasound imaging to measure abdominal muscle structure. The sensory testing, called two-point discrimination, measures how well participants can tell the difference between two nearby points touching the skin using a small measuring tool that lightly touches the skin of the abdomen. Ultrasound imaging uses sound waves to create images of the inside of the body and will be used to measure the thickness and appearance of the abdominal muscles. This study includes two groups of participants: healthy volunteers and individuals with rib fractures.

Healthy volunteers will complete a single study visit lasting about 45 minutes, during which participants will undergo sensory testing, ultrasound imaging, and a short questionnaire. Participants with rib fractures will complete research procedures during their scheduled clinical follow-up visits, which include a baseline visit and three follow-up visits over approximately 12 weeks; research activities, including ultrasound imaging, will add about 30 minutes to each visit.

To investigate the safety, tolerability, PD, and PK of BI 3802876
when administered intravenously in single rising doses following
MABEL dose administration in adult patients with compensated
cirrhosis due to MASH.

The Life's end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks.
This study will enroll approximately 120 participants of any gender at least 40 years of age who are hospice care-eligible with agitation and dementia (HAD). Participants will be randomized (50:50) to either active study drug (T2:C100) or placebo. The double-blind period of this study is 12 weeks.
The LiBBY Open-Label Extension (OLE) Study provides the researchers with the opportunity to further evaluate the effects of the THC/CBD oral combination as a treatment for agitation in HAD. The OLE study is designed to determine whether the benefits of THC/CBD are sustained over time, and whether participants initially receiving placebo can also benefit from the treatment. Additionally, the OLE study seeks to explore whether prolonged treatment with THC/CBD improves lifespan, quality of life, and caregiver burden—areas insufficiently studied in terminally ill dementia patients.